Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice

• DOI: 10.2147/ijn.s84565
• Publication Date: 2015-08-07T00:15:45Z
• Authors: Mei Xue; Liang Zhang; Mingxing Yang; Wei Zhang; Xiumin Li; Zhi-min Ou; Zhi-peng Li; Suhuan Liu; Xuejun Li; Shu-yu Yang
• Keywords: Male; 0301 basic medicine; Medicine (General); Berberine; Down-Regulation; Fatty Acids, Nonesterified; Mice; 03 medical and health sciences; R5-920; International Journal of Nanomedicine; Animals; Hypoglycemic Agents; Aspartate Aminotransferases; Original Research; Carnitine O-Palmitoyltransferase; Body Weight; Alanine Transaminase; Organ Size; Lipid Metabolism; Lipids; 3. Good health; Fatty Liver; Disease Models, Animal; Liver; Nanoparticles; Fatty Acid Synthases; Stearoyl-CoA Desaturase

Berberine (BBR) shows very low plasma levels after oral administration due to its poor absorption by the gastrointestinal tract. We have previously demonstrated that BBR showed increased gastrointestinal absorption and enhanced antidiabetic effects in db/db mice after being entrapped into solid lipid nanoparticles (SLNs). However, whether BBR-loaded SLNs (BBR-SLNs) also have beneficial effects on hepatosteatosis is not clear. We investigated the effects of BBR-SLNs on lipid metabolism in the liver using histological staining and reverse transcription polymerase chain reaction analysis. The results showed that oral administration of BBR-SLNs inhibited the increase of body weight and decreased liver weight in parallel with the reduction of serum alanine transaminase and liver triglyceride levels in db/db mice. The maximum drug concentration in the liver was 20-fold higher than that in the blood. BBR-SLNs reduced fat accumulation and lipid droplet sizes significantly in the liver, as indicated by hematoxylin and eosin and Oil Red O staining. The expression of lipogenic genes, including fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD1), and sterol regulatory element-binding protein 1c (SREBP1c) were downregulated, while lipolytic gene carnitine palmitoyltransferase-1 (CPT1) was upregulated in BBR-SLN-treated livers. In summary, we have uncovered an unexpected effect of BBR-SLNs on hepatosteatosis treatment through the inhibition of lipogenesis and the induction of lipolysis in the liver of db/db mice.